Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat cancers: targeted combo shows promise

NCT ID NCT05194995

Disease control Sponsor: Allist Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug (JAB-21822) combined with cetuximab in people with advanced colorectal, small intestine, or appendiceal cancers that have a specific KRAS G12C mutation. Participants must have already tried at least one standard treatment. The goal is to see if the combination is safe and can shrink tumors. This is not a cure, but aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

48 people

The number who actually took part.

Started

Feb 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must be able to provide an archived tumor sample * Histologically or cytologically confirmed advanced colorectal cancer, advanced small intestinal cancer and advanced appendiceal cancer with KRAS p.G12C mutation * Must have received at least 1 prior standard therapy * Must have at least 1 measurable lesion per RECIST v1.1 * Must have adequate organ function * Must be able to swallow and retain orally administered medication Exclusion Criteria: * Has brain metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days * Active infection requiring systemic treatment within 14 days * Active HIV, HBV or HCV * Any severe and/or uncontrolled medical conditions * LVEF\<50% assessed by ECHO * QT interval \>470 msec

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

appendiceal neoplasm appendix cancer colorectal cancer small intestine cancer small intestine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced colorectal cancer Appendiceal cancer Small intestinal cancer

Contacts and locations

Locations

  • Research site01

    Beijing, Beijing Municipality, 100101, China

  • Research site02

    Beijing, Beijing Municipality, 100101, China

  • Research site05

    Zhengzhou, Henan, 450000, China

  • Research site06

    Harbin, Heilongjiang, 150000, China

  • Research site07

    Zhengzhou, Henan, 450000, China

  • Research site08

    Nanchang, Jiangxi, 330000, China

  • Research site09

    Nanjing, Jiangsu, 210000, China

  • Research site11

    Changsha, Hunan, 410000, China

  • Research site12

    Beijing, Beijing Municipality, 100101, China

  • Research site13

    Nanning, Guangxi, 530021, China

  • Research site16

    Linyi, Shandong, 276002, China

  • Research site18

    Wuhan, Hubei, 430079, China

  • Research site19

    Hangzhou, Zhejiang, 310005, China

  • Research site23

    Xi’an, Shanxi, 710000, China

  • Research site28

    Shanghai, Shanghai Municipality, 200032, China

  • Research site29

    Changsha, Hunan, 410000, China

  • Research site31

    Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.